# ZST-101

Source: https://onco.cc/drugs/zst-101/  
OnCo record `zst-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZST-101 is an experimental radioactive medicine from ZEeST Bio for hepatocellular carcinoma, the commonest primary liver cancer. It is in laboratory testing.

## Summary

ZST-101 is the lead programme of ZEeST Bio, a radiotherapeutic built on a theranostic radiopharmaceutical platform for hepatocellular carcinoma, listed as preclinical on the company's pipeline. No clinical data exist.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: ZST-101
- Modality: Theranostic radiopharmaceutical
- Mechanism: A radiopharmaceutical carried into liver tumours by a clinically validated hepatotropic uptake mechanism, designed for both imaging and therapy, as the developer describes.

## Sources

- ZEeST Bio: pipeline: https://zeest.bio/

## Connected records

- companies: [ZEeST Bio](https://onco.cc/companies/zeest-bio/)

---
JSON: https://onco.cc/api/v1/entities/zst-101.json